DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,504 filers reported holding DANAHER CORPORATION in Q4 2019. The put-call ratio across all filers is 1.66 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,453,825 | +107231.2% | 26,013 | +3.8% | 2.17% | +16.2% |
| Q2 2023 | $6,013 | -99.9% | 25,055 | +7.9% | 1.86% | -8.6% |
| Q1 2023 | $5,851,109 | +94516.9% | 23,215 | -0.4% | 2.04% | -20.5% |
| Q4 2022 | $6,184 | -99.9% | 23,299 | +1.6% | 2.56% | -15.2% |
| Q3 2022 | $5,923,000 | -22.8% | 22,932 | -24.3% | 3.02% | -5.7% |
| Q2 2022 | $7,676,000 | -16.8% | 30,278 | -3.8% | 3.21% | +7.6% |
| Q1 2022 | $9,228,000 | -22.8% | 31,459 | -13.5% | 2.98% | +3.8% |
| Q4 2021 | $11,961,000 | +12.5% | 36,353 | +4.1% | 2.87% | -4.1% |
| Q3 2021 | $10,633,000 | +14.0% | 34,927 | +0.5% | 3.00% | +17.1% |
| Q2 2021 | $9,330,000 | +17.3% | 34,768 | -1.6% | 2.56% | +7.7% |
| Q1 2021 | $7,953,000 | +0.4% | 35,332 | -0.9% | 2.38% | -0.6% |
| Q4 2020 | $7,923,000 | +3.6% | 35,668 | +0.4% | 2.39% | -7.5% |
| Q3 2020 | $7,650,000 | +22.1% | 35,526 | +0.3% | 2.58% | +11.9% |
| Q2 2020 | $6,264,000 | +27.1% | 35,426 | -0.5% | 2.31% | +2.2% |
| Q1 2020 | $4,928,000 | -30.4% | 35,607 | -22.8% | 2.26% | -4.9% |
| Q4 2019 | $7,081,000 | +6.8% | 46,139 | +0.5% | 2.38% | -2.6% |
| Q3 2019 | $6,630,000 | +0.6% | 45,902 | -0.4% | 2.44% | -1.9% |
| Q2 2019 | $6,588,000 | +18.7% | 46,099 | +9.6% | 2.49% | +9.8% |
| Q1 2019 | $5,551,000 | +27.0% | 42,043 | -0.8% | 2.26% | +0.3% |
| Q4 2018 | $4,372,000 | -8.6% | 42,399 | -3.7% | 2.26% | +19.7% |
| Q3 2018 | $4,783,000 | +10.8% | 44,021 | +0.6% | 1.89% | +1.3% |
| Q2 2018 | $4,316,000 | +0.9% | 43,738 | +0.1% | 1.86% | -1.4% |
| Q1 2018 | $4,277,000 | +5.7% | 43,680 | +0.2% | 1.89% | +5.9% |
| Q4 2017 | $4,047,000 | +7.8% | 43,596 | -0.4% | 1.78% | +5.3% |
| Q3 2017 | $3,755,000 | -21.6% | 43,778 | -22.9% | 1.69% | -21.6% |
| Q2 2017 | $4,790,000 | -1.3% | 56,760 | +0.0% | 2.16% | -3.7% |
| Q1 2017 | $4,853,000 | +9.4% | 56,736 | -0.5% | 2.24% | +1.4% |
| Q4 2016 | $4,437,000 | -1.1% | 57,003 | -0.4% | 2.21% | -1.5% |
| Q3 2016 | $4,488,000 | -21.7% | 57,251 | +0.9% | 2.25% | -25.9% |
| Q2 2016 | $5,730,000 | +2.5% | 56,732 | -3.7% | 3.03% | +5.7% |
| Q1 2016 | $5,590,000 | +0.3% | 58,929 | -1.8% | 2.87% | -1.1% |
| Q4 2015 | $5,575,000 | +12.5% | 60,026 | +3.2% | 2.90% | +5.0% |
| Q3 2015 | $4,956,000 | -0.4% | 58,162 | +0.0% | 2.76% | +10.6% |
| Q2 2015 | $4,976,000 | +2.5% | 58,141 | +1.7% | 2.50% | +6.2% |
| Q1 2015 | $4,856,000 | +0.1% | 57,197 | +1.1% | 2.35% | -1.5% |
| Q4 2014 | $4,849,000 | +13.9% | 56,572 | +1.0% | 2.39% | +9.3% |
| Q3 2014 | $4,256,000 | +4.9% | 56,019 | +8.7% | 2.18% | +3.2% |
| Q2 2014 | $4,056,000 | +6.9% | 51,517 | +1.8% | 2.12% | +9.7% |
| Q1 2014 | $3,795,000 | -4.9% | 50,596 | -2.1% | 1.93% | -7.8% |
| Q4 2013 | $3,989,000 | +35.7% | 51,670 | +21.9% | 2.09% | +22.8% |
| Q3 2013 | $2,939,000 | +11.5% | 42,399 | +1.8% | 1.70% | +9.4% |
| Q2 2013 | $2,637,000 | – | 41,651 | – | 1.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |